Search Results
Your search for The matches 34839 pages
Showing 5951 - 6000Elotuzumab Plus Pomalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: ELOQUENT-3 Overall Survival Analysis
As reported in the Journal of Clinical Oncology by Meletios A. Dimopoulos, MD, and colleagues, the final overall survival analysis of the phase II ELOQUENT-3 trial showed significant benefit with the addition of elotuzumab to pomalidomide and dexamethasone (EPd) vs pomalidomide and dexamethasone...
Adding CT to X-Ray for Follow-up of Completely Resected NSCLC
In a French phase III trial (IFCT-0302) reported in The Lancet Oncology, Westeel et al found that a strategy including computed tomography (CT) and x-ray vs x-ray alone did not improve overall survival when used in the follow-up of patients with completely resected non–small cell lung cancer...
Anna Sureda, MD, PhD, on Large B-Cell Lymphoma: New Data on Axicabtagene Ciloleucel vs Standard of Care
Anna Sureda, MD, PhD, of the University of Barcelona and the Catalan Institute of Oncology, discusses phase III clinical and patient-reported outcomes from the ZUMA-7 trial, which showed that axicabtagene ciloleucel was superior to second-line standard-of-care treatment in patients 65 years or...
Harry P. Erba, MD, PhD, on AML: New Data on Quizartinib Plus Standard Chemotherapy
Harry P. Erba, MD, PhD, of Duke Cancer Institute, discusses potentially practice-changing phase III results from the QuANTUM-First trial, which showed that adding quizartinib to standard chemotherapy and up to 3 years of continuation therapy led to improvement in overall survival for adults aged 18 ...
Study Examines Effects of Advance Care Planning for Adolescents With Cancer
In a recently published study by Needle et al in JAMA Network Open, University of Minnesota researchers and colleagues say adolescents with cancer deserve a voice in medical decisions made for and about them. “Adolescents with cancer should be given the opportunity to participate in their own...
Proximity to Fracking Sites May Be Associated With Risk of Pediatric Leukemia
Children in Pennsylvania living near unconventional oil and gas developments at birth were two to three times more likely to be diagnosed with leukemia between the ages of 2 and 7 years than children who did not live near this oil and gas activity, after accounting for other factors that could...
Cancer-Related Fatigue Linked to Balance Problems After Chemotherapy for Breast Cancer
For many patients who have received chemotherapy for breast cancer, cancer-related fatigue is a persistent side effect—and one that contributes to ongoing balance problems, suggests a recent paper published by Weschler et al in Rehabilitation Oncology. The new research by Stephen Wechsler, PT, DPT, ...
Rituximab, Lenalidomide, and Ibrutinib With Sequential Addition of Chemotherapy in Newly Diagnosed DLBCL: Smart Start Trial
In a single-institution phase II trial (Smart Start) reported in the Journal of Clinical Oncology, Jason Westin, MD, MS, and colleagues found that initiating treatment with rituximab, lenalidomide, and ibrutinib (RLI) followed by the sequential addition of chemotherapy resulted in high response...
Global Burden of Cancer Attributable to Modifiable Risk Factors in 2019
In an analysis from the Global Burden of Disease Study 2019 reported in The Lancet, researchers from the GBD 2019 Cancer Risk Factors Collaborators found that cancers attributable to behavioral, environmental/occupational, and metabolic risk factors accounted for 44% of all cancer deaths globally...
Durvalumab/Tremelimumab for Previously Treated Patients With Advanced Soft-Tissue and Bone Sarcomas
In a single-center phase II trial reported in The Lancet Oncology, Somaiah et al found that the combination of durvalumab and tremelimumab showed activity in a group of previously treated patients with advanced or metastatic soft-tissue and bone sarcomas of various subtypes. Study Details In the...
Nine Oncology Practices Certified Through ASCO Patient-Centered Cancer Care Certification Pilot
ASCO recently announced that nine outpatient oncology group practices have achieved certification through the new ASCO Patient-Centered Cancer Care Certification pilot based on their adherence to oncology medical home (OMH) standards, a single set of comprehensive, expert-backed standards for...
2023 Hospital Outpatient Payment Proposal Does Not Reflect SCOTUS Ruling on 340B Reimbursement
On July 15, 2022, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule for the 2023 Medicare Hospital Outpatient Prospective Payment System (OPPS). ASCO is assessing the full proposal, but ASCO’s initial analysis is as follows. In June 2022, the Supreme Court ruled that ...
New Guideline Updates Address Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations
Two ASCO guideline updates provide new evidence-based recommendations for the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations.1,2 Among several other updates, these new guidelines add the ALK and ROS1 inhibitor lorlatinib and the PD-L1 immune...
Biden Administration Announces New Model to Improve Cancer Care for Medicare Patients
On June 27, 2022, the Biden Administration, through the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), announced a new model aimed at improving cancer care for Medicare patients and lowering health-care costs. CMS’ Center for Medicare...
Cardiovascular Mortality and Cancer Mortality Over Time Among Cancer Survivors
In an English retrospective cohort study reported in JACC: Cardio-Oncology, Helen Strongman, PhD, of the Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, and colleagues found that cardiovascular mortality ultimately exceeded mortality from common...
Lisocabtagene Maraleucel in Second-Line Treatment of Large B-Cell Lymphoma
On June 24, 2022, lisocabtagene maraleucel was approved for adults with large B-cell lymphoma (LBCL) who have (1) refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or (2) refractory disease to first-line chemoimmunotherapy or relapse...
Anthony S. Fauci, MD, to Step Down From Current Roles in December
Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases (NIAID), announced his intention to step down from his various roles in December 2022. He issued the following statement on August 22: I am announcing today that I will be stepping down from the positions...
Rucaparib Maintenance After Platinum-Based Chemotherapy for Metastatic Urothelial Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Simon J. Crabb, BSc, MBBS, MRCP, PhD, and colleagues found that maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib vs placebo was associated with prolonged progression-free survival in patients with...
Expert Point of View: Javier Cortés, MD, PhD
The invited discussant of the updated APHINITY data was Javier Cortés, MD, PhD, Head of the International Breast Cancer Center in Barcelona. “I think we clearly learned two things from the data. One is that estrogen receptor positivity does not matter in terms of benefit from the addition of...
Racial Trends in Advanced Cervical Cancer in the United States
The steepest annual rise in new cases of advanced cervical cancer in the United States from 2001 to 2018 was among White patients, who were significantly less likely to receive the preventive human papillomavirus (HPV) vaccine or to be screened for the disease, according to research published by...
APHINITY Trial in Patients With HER2-Positive Early Breast Cancer: Update at 8 Years
Updated results from the adjuvant APHINITY trial in HER2-positive early breast cancer, now with a median follow-up of 8.4 years, confirmed the benefit of adding pertuzumab to trastuzumab plus chemotherapy in preventing invasive disease recurrences, but as yet no statistically significant overall...
Crizotinib in Adult and Pediatric ALK-Positive Inflammatory Myofibroblastic Tumors
On July 14, 2022, crizotinib was approved for adult and pediatric patients aged ≥ 1 year with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter studies ADVL0912 (ClinicalTrials.gov...
Study Evaluates UV Protective Behaviors in American Indian and Alaskan Native Populations
Ultraviolet (UV) protection from the sun and avoiding indoor tanning play important roles in reducing a person’s risk for skin cancer, the most common cancer in the United States and one of the most preventable. A recent article published by Yang et al in the Journal of the American Academy of...
Expert Point of View: Katrina S. Pedersen, MD, MS
Katrina S. Pedersen, MD, MS, Assistant Professor of Medicine at Washington University School of Medicine, St. Louis, said while the results of the phase II -SEQUENCE trial1 are encouraging and the drugs are available to translate into the clinic without delay, phase III validation would be needed...
Stem Cell Boost as Salvage Therapy for Severe Hematologic Toxicity After CD19 CAR T-Cell Therapy
In a retrospective study reported in a research letter in Blood Advances, Rejeski et al found that a stem cell boost was successful in treating severe hematologic toxicity in patients who had received CD19 chimeric antigen receptor (CAR) T-cell therapy for refractory B-cell malignancies. Study...
Sequencing Therapies May Improve Overall Survival in Metastatic Pancreatic Cancer
In the first-line treatment of metastatic pancreatic cancer, the sequencing of nab-paclitaxel plus gemcitabine with FOLFOX (fluorouracil, leucovorin, oxaliplatin) resulted in a significant improvement in overall survival at 12 months and in all other efficacy endpoints as compared with the standard ...
Effect of Physical Activity on Disease-Free Survival in Patients Receiving Adjuvant Therapy for Stage III Colon Cancer
As reported in the Journal of Clinical Oncology by Brown et al, a prospective cohort study nested within the phase III CALGB/SWOG 80702/Alliance trial showed that greater volumes of physical activity in patients receiving adjuvant therapy for stage III colon cancer were associated with significant...
Snapshots of Studies of Interest Presented at ASCO 2022
The 2022 ASCO Annual Meeting was filled with important science, engaging data, and several practice-changing abstracts, many of which have been covered in detail on other pages or in earlier issues of The ASCO Post. There were numerous high-impact studies and attendees, whether present at the...
Impact of the Dobbs v Jackson Women’s Health Organization Ruling on Patients With Cancer
As a nonpartisan organization, the American Cancer Society has an overarching goal to improve the lives of patients with cancer and their families. We believe all individuals should have an equitable opportunity to prevent, find, detect, and survive cancer, irrespective of geography. The June 24...
Is Science Getting Closer to Preventing Multiple Myeloma?
About 3 years ago, researchers from Dana-Farber Cancer Institute launched PROMISE (Predicting Progression of Developing Myeloma in a High-Risk Screen Population; ClinicalTrials.gov identifier NCT03689595), a large, ambitious screening study to identify individuals at high risk of developing...
ASCO 2022: Conversations in Colorectal Cancer
On this episode, we’re featuring discussions about data in colorectal cancer that were presented at the 2022 ASCO Annual Meeting. Dr. Michael Overman, of The University of Texas MD Anderson Cancer Center, speaks with two presenters about guiding therapy with circulating tumor DNA and refining...
Expert Point of View: Alexey V. Danilov, MD, PhD
According to Alexey V. Danilov, MD, PhD, Professor and Co-Director, Toni Stephenson Lymphoma Center, City of Hope, diffuse large B-cell lymphoma (DLBCL) refractory to chemotherapy represents an unmet medical need, with data from the SCHOLAR-1 study demonstrating a median overall survival of...
Epcoritamab Under Study in Difficult-to-Treat Large B-Cell Lymphoma
Subcutaneous epcoritamab, a bispecific antibody, has demonstrated deep and durable responses in a large expansion cohort of patients with relapsed or refractory large B-cell lymphoma (LBCL), according to late-breaking data presented during the European Hematology Association (EHA) 2022 Congress in...
Real-World Evidence Confirms Survival Benefit of Durvalumab in Locally Advanced Non–Small Cell Lung Cancer
In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after chemoradiotherapy as a standard of care. Real-world evidence of durvalumab’s effect on overall and...
Atezolizumab Plus Vemurafenib/Cobimetinib for Patients With BRAF V600–Mutated Melanoma and CNS Metastases
In the phase II TRICOTEL study reported in The Lancet Oncology, Reinhard Dummer, MD, and colleagues found that the combination of atezolizumab plus vemurafenib and cobimetinib produced durable intracranial responses in patients with BRAF V600–mutated melanoma and central nervous system (CNS)...
PREMMplus Tool May Assist in Identifying People Likely to Benefit From Multigene Hereditary Cancer Risk Assessment
An online tool developed by researchers and physicians at Dana-Farber Cancer Institute may accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, according to findings reported by Yurgelun et al in the...
Study Tests Strategy for Reducing Colorectal Cancer Risk Among Patients With Familial Adenomatous Polyposis
Researchers from the Mayo Clinic Comprehensive Cancer Center and the Mayo Clinic Center for Individualized Medicine are studying the rare genetic condition called familial adenomatous polyposis, looking for potential ways to prevent colorectal cancer in the general population at an earlier, more...
Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, de Vries et al developed risk models for predicting the development of coronary heart disease and heart failure in patients treated for Hodgkin lymphoma. Study Details The prediction models were developed in a Dutch cohort of 1,433 5-year...
Is Advance Care Planning of Any Value?
An article in The New York Times earlier this year crystallized the dilemma facing health-care providers when they are presented with a patient in a life-threatening situation: Should they rely on advance care directives written years prior to the current medical situation to accurately determine...
Does Exposure to 'Forever Chemical' Elevate Risk of Developing Hepatocellular Carcinoma?
Exposure to a synthetic chemical found widely in the environment may be linked to the development of nonviral hepatocellular carcinoma, according to a new study published by Goodrich et al in JHEP Reports. The chemical—called perfluorooctane sulfate, or PFOS—is one of a class of man-made chemicals...
T-DXd Shows High Intracranial Response Rate in Patients With Active Brain Metastases From HER2-Positive Breast Cancer
In the investigator-initiated, prospective, open-label, single-arm phase II TUXEDO-1 study conducted among patients with newly diagnosed or progressive brain metastases from HER2-positive breast cancer, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) yielded responses according...
Low-Dose Decitabine and Azacitidine in Lower-Risk MDS
As reported in NEJM Evidence by Sasaki et al, extended follow-up of a phase II trial showed good outcomes with low doses of the hypomethylating agents decitabine and azacitidine in previously untreated patients with lower-risk myelodysplastic syndromes (MDS). Study Details The study included 113...
First-Line Lenalidomide/Rituximab vs Rituximab/Chemotherapy With Rituximab Maintenance for Advanced Follicular Lymphoma
As reported in the Journal of Clinical Oncology by Franck Morschhauser, MD, PhD, and colleagues, 6-year results from the second interim analysis of the phase III RELEVANCE trial show similar progression-free and overall survival with lenalidomide/rituximab (R2) vs rituximab/chemotherapy (R-chemo)...
Expert Point of View: Michael Cecchini, MD
The ASCO Post asked Michael Cecchini, MD, Assistant Professor of Medicine and Co-Director of the Colorectal Program in the Center for Gastrointestinal Cancer at Yale School of Medicine and Smilow Cancer Hospital Center, New Haven, to comment on the RATIONALE-306 findings. He said the study...
RATIONALE-306: Survival Benefit Attained With Tislelizumab in Advanced Esophageal Cancer
In patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of the checkpoint inhibitor tislelizumab to first-line chemotherapy significantly improved overall survival vs chemotherapy alone, according to an interim analysis of the global phase III RATIONALE-306 trial....
Study Shows Germline Testing May Be Warranted for All Patients With Lung Cancer
Germline testing may be warranted for all patients with lung cancer, according to research presented by Sorscher et al during the August ASCO Plenary Series Program (Abstract 388570). The retrospective review of nearly 8,000 patients with lung cancer undergoing germline testing found that 14.9% had ...
FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients With Beta-Thalassemia Who Require Regular Blood Transfusions
On August 17, the U.S. Food and Drug Administration (FDA) approved betibeglogene autotemcel (Zynteglo), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. “[This] approval is an important...
Pralsetinib Achieves Tissue-Agnostic Benefits for Patients With RET Fusion–Positive Cancers
The highly selective RET inhibitor pralsetinib was well tolerated and demonstrated robust, durable responses in patients with RET fusion–positive cancers regardless of tumor type, according to results from the international phase I/II ARROW trial. Results from the trial were published in Nature...
Study Reveals Potential Genomic Contributors to the Development of DLBCL
By searching previously ignored regions of the genome, researchers have found a multitude of new genetic mutations that may contribute to diffuse large B-cell lymphoma (DLBCL). These findings were published by Bal et al in Nature. “Our findings not only show that these mutations can contribute to...
WBI With Boost After Breast-Conserving Surgery in Non–Low-Risk DCIS
As reported in The Lancet by Chua et al, the phase III BIG 3-07/TROG 07.01 trial has shown reduced risk of local recurrence with vs without tumor bed boost after conventional or hypofractionated whole-breast irradiation (WBI) in women receiving breast-conserving surgery for non–low-risk ductal...
